Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTF8JAT)

• DTT Name: SLC5A2 messenger RNA (SLC5A2 mRNA)
• Synonyms: Solute carrier family 5 member 2 (mRNA); Na(+)/glucose cotransporter 2 (mRNA); Low affinity sodium-glucose cotransporter (mRNA)
• Gene Name: SLC5A2
• DTT Type: Clinical trial target; [1]
• BioChemical Class: mRNA target
• UniProt ID: SC5A2_HUMAN
• TTD ID: T81100
• Sequence:
  MEEHTEAGSAPEMGAQKALIDNPADILVIAAYFLLVIGVGLWSMCRTNRGTVGGYFLAGR
  SMVWWPVGASLFASNIGSGHFVGLAGTGAASGLAVAGFEWNALFVVLLLGWLFAPVYLTA
  GVITMPQYLRKRFGGRRIRLYLSVLSLFLYIFTKISVDMFSGAVFIQQALGWNIYASVIA
  LLGITMIYTVTGGLAALMYTDTVQTFVILGGACILMGYAFHEVGGYSGLFDKYLGAATSL
  TVSEDPAVGNISSFCYRPRPDSYHLLRHPVTGDLPWPALLLGLTIVSGWYWCSDQVIVQR
  CLAGKSLTHIKAGCILCGYLKLTPMFLMVMPGMISRILYPDEVACVVPEVCRRVCGTEVG
  CSNIAYPRLVVKLMPNGLRGLMLAVMLAALMSSLASIFNSSSTLFTMDIYTRLRPRAGDR
  ELLLVGRLWVVFIVVVSVAWLPVVQAAQGGQLFDYIQAVSSYLAPPVSAVFVLALFVPRV
  NEQGAFWGLIGGLLMGLARLIPEFSFGSGSCVQPSACPAFLCGVHYLYFAIVLFFCSGLL
  TLTVSLCTAPIPRKHLHRLVFSLRHSKEEREDLDADEQQGSSLPVQNGCPESAMEMNEPQ
  APAPSLFRQCLLWFCGMSRGGVGSPPPLTQEEAAAAARRLEDISEDPSWARVVNLNALLM
  MAVAVFLWGFYA
• Function: Has a Na(+) to glucose coupling ratio of 1:1. Sodium-dependent glucose transporter.
• Reactome Pathway:
  Na+-dependent glucose transporters (R-HSA-428808)
  Inositol transporters (R-HSA-429593)
  Hexose transport (R-HSA-189200)

Molecular Interaction Atlas (MIA) of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bexagliflozin	DMK56G0	Type 2 diabetes	5A11	Approved	[1]

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ISIS-SGLT2	DMDKAIC	Type-2 diabetes	5A11	Phase 1	[2]

15 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
10-methoxy-N(1)-methylburnamine-17-O-veratrate	DMJW25X	Discovery agent	N.A.	Investigative	[3]
ACEROGENIN B	DMVQ30P	Discovery agent	N.A.	Investigative	[4]
Acerogenin C	DMNETSX	Discovery agent	N.A.	Investigative	[4]
Alstiphyllanine D	DM2FLDJ	Discovery agent	N.A.	Investigative	[3]
Alstiphyllanine E	DMTNQ5E	Discovery agent	N.A.	Investigative	[3]
Alstiphyllanine F	DMKRAEW	Discovery agent	N.A.	Investigative	[3]
Burnamine-17-O-3',4',5'-trimethoxybenzoate	DMBO0WI	Discovery agent	N.A.	Investigative	[3]
FORMONONETIN	DM7WFZ8	Discovery agent	N.A.	Investigative	[5]
KURAIDIN	DMLDUJ1	Discovery agent	N.A.	Investigative	[5]
KURARINONE	DMH0G8W	Discovery agent	N.A.	Investigative	[5]
Kushenol N	DMY13UR	Discovery agent	N.A.	Investigative	[5]
MAACKIAIN	DMDHGM2	Discovery agent	N.A.	Investigative	[5]
O-spiroketal glucoside	DM3FS62	Discovery agent	N.A.	Investigative	[6]
SERGLIFLOZIN A	DM6FVCE	Discovery agent	N.A.	Investigative	[7]
Sophoraflavanone G	DMBTMN5	Discovery agent	N.A.	Investigative	[5]

Molecular Expression Atlas (MEA) of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Type 2 diabetes	5A11	Liver tissue	3.26E-01	-0.09	-0.37

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
• [3] Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
• [4] Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1070-4.
• [5] Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
• [6] ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem. 2010 Jun 15;18(12):4422-32.
• [7] Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners. Bioorg Med Chem. 2010 Mar 15;18(6):2178-2194.